Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook
Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper
- Metric
- revenue
- Period
- full-year 2026
- New
- $114.0 million to $117.0 million
- Direction
- raise
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The combination of record revenue, sharply higher operating margin, and raised guidance provides a clear basis for near-term estimate revisions and positioning.
Market read
Guidance raise and profitability improvement are the primary drivers for trading, especially for small/mid-cap earnings momentum and margin-focused investors.
What to watch
The filing notes a reduction in net plasma centers (down 46 over 12 months) and higher operating expenses excluding contingent consideration; traders should watch whether utilization gains offset center contraction going forward.
Background
The 8-K (Item 2.02) includes Paysign’s Q2 2026 financial results and an updated full-year 2026 outlook.
Ticker impact
Paysign reported Q2 2026 results with record revenue and raised full-year outlook, including revenue $114.0M to $117.0M and Adjusted EBITDA $35.0M to $38.0M.
Bias toward upside revisions and support for the stock, with follow-through dependent on sustaining plasma utilization and pharma program additions.
The filing discloses multiple fresh, decision-relevant datapoints: record revenue (+48.1% YoY), operating margin expansion (24.8% vs 7.5% YoY), and explicit full-year guidance ranges.
Market effects
Improving margins and growth in patient affordability and plasma processing could be read across to investor appetite for life-sciences payments and patient engagement platforms.
Limited, as the disclosure is company-specific with no broader regional policy or macro catalyst.
Low, since the news is not tied to global macro or cross-border regulatory actions.
Counterpoint
Margin expansion may be partly mix-driven (pharma mix) and could normalize if plasma center utilization or pharma program growth slows.
Key entities
- companyPaysign, Inc.
NASDAQ-listed patient affordability and plasma donor compensation payments platform reporting Q2 2026 results and raising full-year outlook.
- personMark Newcomer
CEO quoted in the release discussing growth momentum and margin expansion.
